PFM
DNA.WS

Privium Fund Management’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Privium Fund Management’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-195,263
Closed -$172K – 293
2022
Q1 		$172K Sell
195,263
-112,408
-37% -$125K 0.04% 143
2021
Q4 		$738K Buy
+307,671
New +$995K 0.15% 65

Other funds holding DNA.WS

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DPCM
Darlington Partners Capital Management Greenbrae, California $2.23B AUM 16.2% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Privium Fund Management's DNA.WS Position: Q2 2022 in Review

Privium Fund Management sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q2 2022, closing a stake of 195,263 shares — an estimated $172K sold.

Privium Fund Management first reported a position in DNA.WS in Q4 2021 and held it in 2 quarters. The position peaked at $738K in Q4 2021. 49 funds tracked by Wall St. Rank hold DNA.WS as of Q2 2022.

  • Privium Fund Management reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q2 2022 after selling out during the quarter.
  • Privium Fund Management sold 195,263 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q2 2022, an estimated $172K.
  • Privium Fund Management first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q4 2021 and held it in 2 quarters.
  • Privium Fund Management's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $738K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q2 2022.

Based on Privium Fund Management's 13F filing for Q2 2022, filed 28 Jul 2022.